Cost Plus Drugs Targets Custom Rare Disease Medicines to Disrupt Specialized Markets

By Ed Silverman · STAT News · 2026-10-21

According to STAT News, Mark Cuban and CEO Alex Oshmyansky intend to expand the Cost Plus Drugs portfolio into the manufacturing of small-batch treatments for rare conditions. The company plans to utilize its existing facility to shift between specialized drug batches, potentiall

According to STAT News, Mark Cuban and CEO Alex Oshmyansky intend to expand the Cost Plus Drugs portfolio into the manufacturing of small-batch treatments for rare conditions. The company plans to utilize its existing facility to shift between specialized drug batches, potentiall